Journal Article
. 2013 Jun; 19(15):4196-205.
doi: 10.1158/1078-0432.CCR-13-0804.

Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence

Yi Zhang 1 Catherine A Schnabel  Brock E Schroeder  Piiha-Lotta Jerevall  Rachel C Jankowitz  Tommy Fornander  Olle Stål  Adam M Brufsky  Dennis Sgroi  Mark G Erlander  
Affiliations
  • PMID: 23757354
  •     57 citations

Abstract

Purpose: Residual risk of relapse remains a substantial concern for patients with hormone receptor-positive breast cancer, with approximately half of all disease recurrences occurring after five years of adjuvant antiestrogen therapy.

Experimental Design: The objective of this study was to examine the prognostic performance of an optimized model of Breast Cancer Index (BCI), an algorithmic gene expression-based signature, for prediction of early (0-5 years) and late (>5 years) risk of distant recurrence in patients with estrogen receptor-positive (ER(+)), lymph node-negative (LN(-)) tumors. The BCI model was validated by retrospective analyses of tumor samples from tamoxifen-treated patients from a randomized prospective trial (Stockholm TAM, n = 317) and a multi-institutional cohort (n = 358).

Results: Within the Stockholm TAM cohort, BCI risk groups stratified the majority (∼65%) of patients as low risk with less than 3% distant recurrence rate for 0 to 5 years and 5 to 10 years. In the multi-institutional cohort, which had larger tumors, 55% of patients were classified as BCI low risk with less than 5% distant recurrence rate for 0 to 5 years and 5 to 10 years. For both cohorts, continuous BCI was the most significant prognostic factor beyond standard clinicopathologic factors for 0 to 5 years and more than five years.

Conclusions: The prognostic sustainability of BCI to assess early- and late-distant recurrence risk at diagnosis has clinical use for decisions of chemotherapy at diagnosis and for decisions for extended adjuvant endocrine therapy beyond five years.

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Dennis C Sgroi, Ivana Sestak, +9 authors, Mitch Dowsett.
Lancet Oncol, 2013 Sep 17; 14(11). PMID: 24035531    Free PMC article.
Highly Cited.
p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
Mitsugu Yamamoto, Mitsuchika Hosoda, +6 authors, Hiroko Yamashita.
Cancer Sci, 2013 Oct 15; 105(1). PMID: 24118529    Free PMC article.
An unmet need: tailoring extended adjuvant endocrine therapy.
G Bianchini, L Gianni.
Br J Cancer, 2013 Nov 21; 109(12). PMID: 24253504    Free PMC article.
How do I recommend extended adjuvant hormonal therapy?
Amitkumar Mehta, John T Carpenter.
Curr Treat Options Oncol, 2013 Dec 18; 15(1). PMID: 24338340
Review.
Genomic profiling in luminal breast cancer.
Oleg Gluz, Daniel Hofmann, +3 authors, Nadia Harbeck.
Breast Care (Basel), 2014 Feb 20; 8(6). PMID: 24550749    Free PMC article.
Review.
Markers for the identification of late breast cancer recurrence.
Ivana Sestak, Jack Cuzick.
Breast Cancer Res, 2015 Apr 08; 17. PMID: 25848913    Free PMC article.
Review.
Developing a new generation of breast cancer clinical gene expression tests.
Zuzana Kos, Torsten O Nielsen.
Breast Cancer Res, 2014 Jan 01; 16(4). PMID: 25928431    Free PMC article.
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, +6 authors, Panel Members.
Ann Oncol, 2015 May 06; 26(8). PMID: 25939896    Free PMC article.
Highly Cited.
The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.
Kathleen Van Asten, An Poppe, +4 authors, Patrick Neven.
Curr Treat Options Oncol, 2015 Jun 03; 16(7). PMID: 26031545
Review.
Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Tara Sanft, Bilge Aktas, +11 authors, Lajos Pusztai.
Breast Cancer Res Treat, 2015 Nov 19; 154(3). PMID: 26578401    Free PMC article.
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
Dennis C Sgroi, Judy-Anne W Chapman, +10 authors, Michael Pollak.
Breast Cancer Res, 2016 Jan 06; 18(1). PMID: 26728744    Free PMC article.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, +11 authors, American Society of Clinical Oncology.
J Clin Oncol, 2016 Feb 10; 34(10). PMID: 26858339    Free PMC article.
Highly Cited. Review.
Translating RNA sequencing into clinical diagnostics: opportunities and challenges.
Sara A Byron, Kendall R Van Keuren-Jensen, +2 authors, David W Craig.
Nat Rev Genet, 2016 Mar 22; 17(5). PMID: 26996076    Free PMC article.
Highly Cited. Review.
Identification and prioritization of candidate genes for symptom variability in breast cancer survivors based on disease characteristics at the cellular level.
Theresa A Koleck, Yvette P Conley.
Breast Cancer (Dove Med Press), 2016 Mar 30; 8. PMID: 27022301    Free PMC article.
MetaKTSP: a meta-analytic top scoring pair method for robust cross-study validation of omics prediction analysis.
SungHwan Kim, Chien-Wei Lin, George C Tseng.
Bioinformatics, 2016 May 07; 32(13). PMID: 27153719    Free PMC article.
Weighted K-means support vector machine for cancer prediction.
SungHwan Kim.
Springerplus, 2016 Aug 12; 5(1). PMID: 27512621    Free PMC article.
Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer.
Pattaraporn Wangchinda, Suthinee Ithimakin.
World J Surg Oncol, 2016 Aug 26; 14(1). PMID: 27557635    Free PMC article.
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.
Sarah M Bernhardt, Pallave Dasari, +3 authors, Wendy V Ingman.
Front Oncol, 2016 Nov 30; 6. PMID: 27896218    Free PMC article.
Review.
Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy.
Birte Hellwig, Katrin Madjar, +11 authors, Jörg Rahnenführer.
PLoS One, 2016 Dec 08; 11(12). PMID: 27926932    Free PMC article.
Meta-analytic support vector machine for integrating multiple omics data.
SungHwan Kim, Jae-Hwan Jhong, JungJun Lee, Ja-Yong Koo.
BioData Min, 2017 Feb 06; 10. PMID: 28149325    Free PMC article.
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.
David M Hyams, Eric Schuur, +7 authors, Aníbal Nuñez De Pierro.
J Surg Oncol, 2017 Feb 18; 115(6). PMID: 28211064    Free PMC article.
Review.
Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy.
Ivana Sestak.
Breast Care (Basel), 2017 Aug 09; 12(3). PMID: 28785181    Free PMC article.
Review.
Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer.
Brock Schroeder, Yi Zhang, +4 authors, Catherine A Schnabel.
NPJ Breast Cancer, 2017 Aug 11; 3. PMID: 28795152    Free PMC article.
ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy.
Fangbin Song, Jianbing Zhang, +6 authors, Junming Xu.
Onco Targets Ther, 2017 Oct 19; 10. PMID: 29042797    Free PMC article.
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.
Prema P Peethambaram, Tanya L Hoskin, +3 authors, Judy C Boughey.
NPJ Breast Cancer, 2017 Oct 27; 3. PMID: 29067357    Free PMC article.
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Hege O Ohnstad, Elin Borgen, +11 authors, Bjørn Naume.
Breast Cancer Res, 2017 Nov 16; 19(1). PMID: 29137653    Free PMC article.
Endocrine Therapy for Early Breast Cancer: Updated Review.
Alexander Tremont, Jonathan Lu, John T Cole.
Ochsner J, 2017 Dec 13; 17(4). PMID: 29230126    Free PMC article.
Review.
Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).
Jame Abraham, Humberto Caldera, +11 authors, Chuck Vogel.
Breast Cancer Res Treat, 2018 Jan 21; 169(1). PMID: 29352368    Free PMC article.
Review.
Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.
Stephen M Schleicher, Maura N Dickler.
Curr Breast Cancer Rep, 2018 Feb 06; 9(4). PMID: 29399271    Free PMC article.
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ivana Sestak, Richard Buus, +9 authors, Mitch Dowsett.
JAMA Oncol, 2018 Feb 17; 4(4). PMID: 29450494    Free PMC article.
Highly Cited.
Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer.
Onur Esbah, Berna Oksuzoglu.
Indian J Med Res, 2018 Mar 08; 146(5). PMID: 29512598    Free PMC article.
Review.
Understanding Biomarkers in Early-Stage Invasive Breast Cancer: Tools From the ASCO Clinical Guideline.
Kelley D Mayden.
J Adv Pract Oncol, 2016 Sep 01; 7(6). PMID: 29588871    Free PMC article.
Review.
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Mitch Dowsett, Ivana Sestak, +5 authors, Jack Cuzick.
J Clin Oncol, 2018 Apr 21; 36(19). PMID: 29676944    Free PMC article.
Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling.
S Aggarwal, A Vaid, +10 authors, D Doval.
South Asian J Cancer, 2018 May 04; 7(2). PMID: 29721472    Free PMC article.
Addressing the challenges of applying precision oncology.
Seung Ho Shin, Ann M Bode, Zigang Dong.
NPJ Precis Oncol, 2018 Jun 07; 1(1). PMID: 29872710    Free PMC article.
Review.
Genomic Testing in the Management of Early-Stage Breast Cancer.
Sima Ehsani, Kari Braun Wisinski.
J Clin Outcomes Manag, 2017 May 01; 24(5). PMID: 30158821    Free PMC article.
An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers.
André Filipe Vieira, Fernando Schmitt.
Front Med (Lausanne), 2018 Sep 21; 5. PMID: 30234119    Free PMC article.
Review.
Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers.
Wenyong Tan, Ming Yang, +2 authors, Weixi Shen.
Cancer Manag Res, 2018 Oct 24; 10. PMID: 30349367    Free PMC article.
Review.
Panoptic View of Prognostic Models for Personalized Breast Cancer Management.
Geetanjali Saini, Karuna Mittal, +3 authors, Ritu Aneja.
Cancers (Basel), 2019 Sep 11; 11(9). PMID: 31500225    Free PMC article.
Review.
Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients.
Kjersti Tjensvoll, Oddmund Nordgård, +3 authors, Bjørnar Gilje.
BMC Cancer, 2019 Nov 23; 19(1). PMID: 31752747    Free PMC article.
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
J M S Bartlett, D C Sgroi, +8 authors, D W Rea.
Ann Oncol, 2019 Sep 11; 30(11). PMID: 31504126    Free PMC article.
Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Hatem Soliman, Susanne Wagner, +9 authors, William Gradishar.
Ann Surg Oncol, 2020 Jan 08; 27(3). PMID: 31907749    Free PMC article.
Indications for prognostic gene expression profiling in early breast cancer.
Erin F Cobain, Daniel F Hayes.
Curr Treat Options Oncol, 2015 May 02; 16(5). PMID: 25929335
Review.
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Joseph Sparano, Anne O'Neill, +5 authors, Kathy D Miller.
JAMA Oncol, 2018 Jul 29; 4(12). PMID: 30054636    Free PMC article.
Highly Cited.
Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage.
Jieun Koh, Min Jung Kim.
Korean J Radiol, 2019 Jan 11; 20(1). PMID: 30627023    Free PMC article.
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
A Matikas, T Foukakis, S Swain, J Bergh.
Ann Oncol, 2019 May 28; 30(7). PMID: 31131397    Free PMC article.
Review.
Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer.
Steven A Buechler, Kathryn P Gray, +7 authors, Meredith M Regan.
JNCI Cancer Spectr, 2020 Apr 28; 3(4). PMID: 32337480    Free PMC article.
Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow.
Johanna M Buschhaus, Brock A Humphries, +7 authors, Gary D Luker.
Oncogene, 2020 Jul 18; 39(34). PMID: 32678295    Free PMC article.
Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences.
Ana Tablante Nunes, Deborah E Collyar, Lyndsay N Harris.
JNCI Cancer Spectr, 2017 Dec 11; 1(1). PMID: 31360834    Free PMC article.
Review.
Endocrine Therapy in Early Breast Cancer.
Katja Krauss, Elmar Stickeler.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982643    Free PMC article.
Review.
A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer.
Caijin Lin, Jiayi Wu, +8 authors, Li Zhu.
Front Oncol, 2020 Oct 13; 10. PMID: 33042787    Free PMC article.
Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment.
Arthur Foulon, Pierrick Theret, Lise Rodat-Despoix, Philippe Kischel.
Cancers (Basel), 2020 Sep 20; 12(9). PMID: 32947780    Free PMC article.
Review.
Multidimensional Machine Learning Personalized Prognostic Model in an Early Invasive Breast Cancer Population-Based Cohort in China: Algorithm Validation Study.
Xiaorong Zhong, Ting Luo, +13 authors, Hong Zheng.
JMIR Med Inform, 2020 Nov 10; 8(11). PMID: 33164899    Free PMC article.
Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients.
Camille Moreau-Bachelard, Loïc Campion, +6 authors, Jean-Sébastien Frénel.
Cancers (Basel), 2020 Dec 17; 12(12). PMID: 33322473    Free PMC article.
Advanced Approaches to Breast Cancer Classification and Diagnosis.
M Zubair, S Wang, N Ali.
Front Pharmacol, 2021 Mar 16; 11. PMID: 33716731    Free PMC article.
Review.
Factors associated with late risks of breast cancer-specific mortality in the SEER registry.
José P Leone, Carlos T Vallejo, +8 authors, Nancy U Lin.
Breast Cancer Res Treat, 2021 Apr 25; 189(1). PMID: 33893907    Free PMC article.
The Signal Transducer IL6ST (gp130) as a Predictive and Prognostic Biomarker in Breast Cancer.
Carlos Martínez-Pérez, Jess Leung, +4 authors, Arran K Turnbull.
J Pers Med, 2021 Jul 03; 11(7). PMID: 34210062    Free PMC article.
Review.